Bayer AG NA Total Liabilities
Bayer AG NA total liabilities. Based on the latest financial reports, Bayer AG NA (BAYN) has total liabilities worth €84.54 Billion EUR (≈ $98.84 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bayer AG NA liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Bayer AG NA (1998–2025)
Total liabilities of Bayer AG NA from 1998 to 2025. This chart illustrates how Bayer AG NA's total liabilities have evolved over time, based on quarterly financial data. Explore Bayer AG NA strategic investment ratio to see how much of total assets are deployed in long-term investments.
Bayer AG NA Competitors by Total Liabilities
The table below lists competitors of Bayer AG NA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Old Dominion Freight Line Inc
NASDAQ:ODFL
|
USA | $1.19 Billion |
|
Legrand SA
PA:LR
|
France | €11.95 Billion |
|
Carnival Corporation
NYSE:CCL
|
USA | $38.52 Billion |
|
KB Financial Group
KO:105560
|
Korea | ₩768.60 Trillion |
|
Prudential Financial Inc
NYSE:PRU
|
USA | $738.16 Billion |
|
WEC Energy Group Inc
NYSE:WEC
|
USA | $37.16 Billion |
|
UltraTech Cement Limited
NSE:ULTRACEMCO
|
India | Rs613.38 Billion |
|
PTT Public Company Limited
BK:PTT
|
Thailand | ฿1.84 Trillion |
Liability Composition Analysis (1998–2025)
This chart breaks down Bayer AG NA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bayer AG NA assets under control.
Liquidity & Leverage Metrics
Bayer AG NA Total Liabilities Ratios Explained
Bayer AG NA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.20 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bayer AG NA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bayer AG NA (1998–2025)
The table below shows the annual total liabilities of Bayer AG NA from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €84.54 Billion ≈ $98.84 Billion |
+7.28% |
| 2024-12-31 | €78.81 Billion ≈ $92.13 Billion |
-5.26% |
| 2023-12-31 | €83.18 Billion ≈ $97.25 Billion |
-3.22% |
| 2022-12-31 | €85.95 Billion ≈ $100.49 Billion |
-1.29% |
| 2021-12-31 | €87.07 Billion ≈ $101.80 Billion |
+0.84% |
| 2020-12-31 | €86.35 Billion ≈ $100.95 Billion |
+9.66% |
| 2019-12-31 | €78.74 Billion ≈ $92.06 Billion |
-1.74% |
| 2018-12-31 | €80.14 Billion ≈ $93.69 Billion |
+109.64% |
| 2017-12-31 | €38.23 Billion ≈ $44.69 Billion |
-24.07% |
| 2016-12-31 | €50.34 Billion ≈ $58.85 Billion |
+3.86% |
| 2015-12-31 | €48.47 Billion ≈ $56.67 Billion |
-3.09% |
| 2014-12-31 | €50.02 Billion ≈ $58.47 Billion |
+63.92% |
| 2013-12-31 | €30.51 Billion ≈ $35.67 Billion |
-6.88% |
| 2012-12-31 | €32.77 Billion ≈ $38.31 Billion |
-2.17% |
| 2011-12-31 | €33.49 Billion ≈ $39.16 Billion |
+2.71% |
| 2010-12-31 | €32.61 Billion ≈ $38.12 Billion |
+1.62% |
| 2009-12-31 | €32.09 Billion ≈ $37.52 Billion |
-11.28% |
| 2008-12-31 | €36.17 Billion ≈ $42.29 Billion |
+4.67% |
| 2007-12-31 | €34.56 Billion ≈ $40.40 Billion |
-19.71% |
| 2006-12-31 | €43.04 Billion ≈ $50.32 Billion |
+66.88% |
| 2005-12-31 | €25.79 Billion ≈ $30.15 Billion |
+1.51% |
| 2004-12-31 | €25.41 Billion ≈ $29.70 Billion |
+1.36% |
| 2003-12-31 | €25.07 Billion ≈ $29.30 Billion |
-4.55% |
| 2002-12-31 | €26.26 Billion ≈ $30.70 Billion |
+30.95% |
| 2001-12-31 | €20.05 Billion ≈ $23.45 Billion |
-0.38% |
| 2000-12-31 | €20.13 Billion ≈ $23.53 Billion |
+25.05% |
| 1999-12-31 | €16.10 Billion ≈ $18.82 Billion |
-3.02% |
| 1998-12-31 | €16.60 Billion ≈ $19.40 Billion |
-- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more